Today (2017 C.E. - 2025 C.E.)

This archive spans the years 2017 through 2025, a period marked by rapid advances in clean energy, medicine, technology, and social equity. It collects documented breakthroughs, policy wins, and scientific achievements from the present era. If you want evidence that progress is real and ongoing, this is where to look.

Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment, for article on psilocybin therapy

The world’s first Phase 3 psilocybin clinical trial is about to commence

By / / Good News For Humankind

Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.

School of tuna, for article on tuna recovery

Vast marine protected area in the Pacific Ocean has led to significant rebound in tuna stocks

By / / Good News For Humankind

Marine protected areas can do more than guard what’s inside their borders — and Papahānaumokuākea is proving it. This vast Hawaiian reserve, spanning over 580,000 square miles, was created to protect biodiversity and culturally sacred Indigenous sites, not to boost commercial fishing. Yet catch rates for yellowfin tuna in surrounding waters rose 54%, a spillover effect driven by the monument’s sheer scale. The findings strengthen the global case for ambitious ocean protection, arriving just as momentum builds toward safeguarding 30% of the world’s oceans by 2030.

Good news for public health, for article on CAB-LA HIV prevention, for article on lenacapavir HIV prevention, for article on HIV infections in young men

Zimbabwe becomes first African nation to approve HIV prevention drug

By / / Good News For Humankind

Zimbabwe just became the first country in Africa to approve cabotegravir, a long-acting HIV prevention injection given once every two months — joining only Australia and the United States. For young women and girls especially, that change is huge: a single shot replaces the daily pill regimen that stigma, privacy concerns, and patchy healthcare often make hard to sustain. It builds on a remarkable turnaround, with AIDS-related deaths in Zimbabwe falling from roughly 130,000 in 2002 to about 20,000 in 2021. As advocate Nyasha Sithole put it, ending the epidemic requires a real “basket of tools.” Zimbabwe’s quick action sends a powerful signal that African regulators don’t have to wait in line for life-saving HIV breakthroughs.